Following the Pharmaceutical Benefits Advisory Committee (PBAC) positive recommendation in August 2023, we are thrilled to announce that today, the Pharmaceutical Benefits Scheme (PBS) has expanded its listing of Spinraza to include pre-symptomatic babies with three copies of the Survival of Motor Neuron 2 (SMN2) gene.
This is fantastic news, now providing families of these babies a second treatment option.
Join a powerful community of supporters who are helping tackle spinal muscular atrophy at its very core. Our community relies on us for support and best-practice resources to guide them in living well with SMA, as well as for resources to help raise disease awareness, educate others and advocate for people living with SMA in the wider Australian community.
